엑스탄트 메디컬 홀딩스, Inc.
US ˙ NYSEAM ˙ US98420P3082

SecurityXTNT / Xtant Medical Holdings, Inc.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership987,410 shares
Latest Disclosed Value $ 550,975
Renaissance Technologies Llc reports 7.34% increase in ownership of XTNT / Xtant Medical Holdings, Inc.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 987,410 shares of Xtant Medical Holdings, Inc. (US:XTNT) valued at $550,975 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 919,860 shares of Xtant Medical Holdings, Inc.. This represents a change in shares of 7.34% during the quarter. The current value of the position is $454,307 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F XTANT MED HLDGS COM NEW 98420P308 987,410 67,550 7.34 551 -23.72 0.0009
2026-02-12 2025-12-31 13F XTANT MED HLDGS COM NEW 98420P308 919,860 205,945 28.85 721 55.72 0.0011
2025-11-13 2025-09-30 13F XTANT MED HLDGS COM NEW 98420P308 713,915 63,205 9.71 463 -3.54 0.0006
2025-08-13 2025-06-30 13F XTANT MED HLDGS COM NEW 98420P308 650,710 -60,500 -8.51 481 43.71 0.0006
2025-05-14 2025-03-31 13F XTANT MED HLDGS COM NEW 98420P308 711,210 -86,823 -10.88 334 -5.38 0.0005
2025-02-13 2024-12-31 13F XTANT MED HLDGS COM NEW 98420P308 798,033 103,825 14.96 354 -24.73 0.0005
2024-11-13 2024-09-30 13F XTANT MED HLDGS COM NEW 98420P308 694,208 -9,602 -1.36 469 5.87 0.0007
2024-08-09 2024-06-30 13F XTANT MED HLDGS COM NEW 98420P308 703,810 -59,500 -7.79 443 0.0008
2024-05-13 2024-03-31 13F XTANT MED HLDGS COM NEW 98420P308 763,310 22,400 3.02 1 0.0014
2024-02-13 2023-12-31 13F XTANT MED HLDGS COM NEW 98420P308 740,910 71,172 10.63 1 0.0013
2023-11-14 2023-09-30 13F XTANT MED HLDGS COM NEW 98420P308 669,738 72,728 12.18 1 0.0013
2023-08-11 2023-06-30 13F XTANT MED HLDGS COM NEW 98420P308 597,010 -5,800 -0.96 1 0.0008
2023-05-12 2023-03-31 13F XTANT MED HLDGS COM NEW 98420P308 602,810 -3,500 -0.58 0 0.0005
2023-02-13 2022-12-31 13F XTANT MED HLDGS COM NEW 98420P308 606,310 -20,900 -3.33 0 -100.00 0.0005
2022-11-14 2022-09-30 13F XTANT MED HLDGS COM NEW 98420P308 627,210 -43,690 -6.51 451 29.23 0.0006
2022-08-12 2022-06-30 13F XTANT MED HLDGS COM NEW 98420P308 670,900 4,700 0.71 349 -22.96 0.0004
2022-05-13 2022-03-31 13F XTANT MED HLDGS COM NEW 98420P308 666,200 -55,400 -7.68 453 12.13 0.0005
2022-02-11 2021-12-31 13F XTANT MED HLDGS COM NEW 98420P308 721,600 40,800 5.99 404 -46.56 0.0005
2021-11-12 2021-09-30 13F XTANT MED HLDGS COM NEW 98420P308 680,800 -331,200 -32.73 756 -54.18 0.0010
2021-08-13 2021-06-30 13F XTANT MED HLDGS COM NEW 98420P308 1,012,000 90,229 9.79 1,650 -24.14 0.0021
2021-05-13 2021-03-31 13F XTANT MED HLDGS COM NEW 98420P308 921,771 294,081 46.85 2,175 189.61 0.0027
2021-02-10 2020-12-31 13F XTANT MED HLDGS COM NEW 98420P308 627,690 251,002 66.63 751 142.26 0.0008
2020-11-13 2020-09-30 13F XTANT MED HLDGS COM NEW 98420P308 376,688 152,000 67.65 310 53.47 0.0003
2020-08-13 2020-06-30 13F XTANT MED HLDGS COM NEW 98420P308 224,688 135,927 153.14 202 242.37 0.0002
2020-05-14 2020-03-31 13F XTANT MED HLDGS COM NEW 98420P308 88,761 4,700 5.59 59 -55.97 0.0001
2020-02-13 2019-12-31 13F XTANT MED HLDGS COM NEW 98420P308 84,061 3,300 4.09 134 -41.48 0.0001
2019-11-13 2019-09-30 13F XTANT MED HLDGS COM NEW 98420P308 80,761 6,100 8.17 229 2.23 0.0002
2019-08-12 2019-06-30 13F XTANT MED HLDGS COM NEW 98420P308 74,661 7,500 11.17 224 9.27 0.0002
2019-05-14 2019-03-31 13F XTANT MED HLDGS COM NEW 98420P308 67,161 11,113 19.83 205 127.78 0.0002
2019-02-12 2018-12-31 13F XTANT MED HLDGS COM NEW 98420P308 56,048 5,700 11.32 90 -53.61 0.0001
2018-11-13 2018-09-30 13F XTANT MED HLDGS COM NEW 98420P308 50,348 6,700 15.35 194 -19.83 0.0002
2018-08-13 2018-06-30 13F/A-1 XTANT MED HLDGS COM NEW 98420P308 43,648 3,400 8.45 242 -23.90 0.0003
2018-08-13 2018-06-30 13F XTANT MED HLDGS COM NEW 98420P308 40,248 318
2018-05-14 2018-03-31 13F XTANT MED HLDGS COM NEW 98420P308 40,248 40,248 -86.21 318 90.42 0.0003
2015-08-14 2015-06-30 13F BACTERIN INTL HLDGS COM NEW 05644R200 0 -16,100 -100.00 0 -100.00
2015-05-13 2015-03-31 13F BACTERIN INTL HLDGS COM NEW 05644R200 16,100 16,100 66 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.